Clinical Trial Update: A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide [Phase 1, Phase 2]

View source ↗

Summary

Trial update for an injectable IMM0306 in combination with lenalidomide for B-cell non-Hodgkin's lymphoma across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• IMM0306
• Lenalidomide (lenalidomide)

Snippet

Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Conditions: B-cell Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN